Literature DB >> 29421995

New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension.

Valentina Mercurio1,2, Anna Bianco2, Giacomo Campi2, Alessandra Cuomo2, Nermin Diab3, Angela Mancini2, Paolo Parrella2, Mario Petretta2, Paul M Hassoun1, Domenico Bonaduce2.   

Abstract

Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Pulmonary arterial hypertension; gene therapy; immunity; inflammation; initial combination therapy; macitentan; metabolism; pulmonary arterial denervation ; riociguat; selexipag; serotonin.

Mesh：

Substances：

Year:  2019        PMID： 29421995     DOI： 10.2174/0929867325666180201095743

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN： 0929-8673            Impact factor:   4.530


  9 in total

Review 1.  Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.

Authors:  George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

2.  Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension.

Authors:  Mario Naranjo; Valentina Mercurio; Hussein Hassan; Noura Alturaif; Alessandra Cuomo; Umberto Attanasio; Nermin Diab; Sarina K Sahetya; Monica Mukherjee; Steven Hsu; Aparna Balasubramanian; Catherine E Simpson; Rachel Damico; Todd M Kolb; Stephen C Mathai; Paul M Hassoun
Journal:  ERJ Open Res       Date:  2022-05-16

Review 3.  Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment.

Authors:  Umberto Attanasio; Alessandra Cuomo; Flora Pirozzi; Stefania Loffredo; Pasquale Abete; Mario Petretta; Gianni Marone; Domenico Bonaduce; Amato De Paulis; Francesca Wanda Rossi; Carlo Gabriele Tocchetti; Valentina Mercurio
Journal:  Int J Mol Sci       Date:  2020-06-22       Impact factor: 5.923

4.  Modulation of Redox Signaling in Chronic Diseases and Regenerative Medicine.

Authors:  Serena Zacchigna; Laura Sartiani; Claudia Penna; Gilda Varricchi; Carlo G Tocchetti
Journal:  Oxid Med Cell Longev       Date:  2019-04-23       Impact factor: 6.543

5.  Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways.

Authors:  Guosen Yan; Jinxia Wang; Tao Yi; Junfen Cheng; Haixu Guo; Yuan He; Xiaorong Shui; Zeyong Wu; Shian Huang; Wei Lei
Journal:  Pulm Circ       Date:  2019-11-05       Impact factor: 2.886

Review 6.  Subgroup Analysis in Pulmonary Hypertension-Specific Therapy Clinical Trials: A Systematic Review.

Authors:  Héctor Rodríguez-Ramallo; Nerea Báez-Gutiérrez; Remedios Otero-Candelera; Laila Abdel-Kader Martín
Journal:  J Pers Med       Date:  2022-05-25

7.  Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography.

Authors:  Valentina Mercurio; Hussein J Hassan; Mario Naranjo; Alessandra Cuomo; Jeremy A Mazurek; Paul R Forfia; Aparna Balasubramanian; Catherine E Simpson; Rachel L Damico; Todd M Kolb; Stephen C Mathai; Steven Hsu; Monica Mukherjee; Paul M Hassoun
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

8.  Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats.

Authors:  Yi Tong; Qian Jiao; Yuanru Liu; Jiankun Lv; Rui Wang; Lili Zhu
Journal:  Front Pharmacol       Date:  2018-09-21       Impact factor: 5.810

9.  The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction.

Authors:  I-Chen Chen; Jao-Yu Lin; Yi-Ching Liu; Chee-Yin Chai; Jwu-Lai Yeh; Jong-Hau Hsu; Bin-Nan Wu; Zen-Kong Dai
Journal:  Int J Med Sci       Date:  2020-09-16       Impact factor: 3.738
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.